CN1938025A - 影响血管生成的化合物及其使用方法 - Google Patents
影响血管生成的化合物及其使用方法 Download PDFInfo
- Publication number
- CN1938025A CN1938025A CNA2005800105055A CN200580010505A CN1938025A CN 1938025 A CN1938025 A CN 1938025A CN A2005800105055 A CNA2005800105055 A CN A2005800105055A CN 200580010505 A CN200580010505 A CN 200580010505A CN 1938025 A CN1938025 A CN 1938025A
- Authority
- CN
- China
- Prior art keywords
- angiogenesis
- organism
- tissue
- cell
- chemical compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
化合物 | 每种细胞类型IC50值 | |||||
HUVEC | HDMEC | SMC | 成纤维细胞 | A375 | RENCA | |
派克昔林 | 1.0×10-5 | 1.1×10-5 | 1.4×10-5 | 1.2×10-5 | 2.5×10-5 | 7.6×10-6 |
红霉素 | >1×10-4 | ~1×10-4 | >1×10-4 | >1×10-4 | >1×10-4 | 5.6×10-5 |
化合物 | 每种细胞类型的IC50值 | |||||
HUVEC | HDMEC | SMC | 成纤维细胞 | A375 | RENCA | |
派克昔林 | 8.4×10-6 | 8.0×10-6 | 3.2×10-5 | 5.2×10-6 | 1.0×10-5 | 5.0×10-6 |
化合物 | 无VEGFR-2抑制剂 | 有VEGFR-2抑制剂 |
派克昔林 | 5.4×10-6 | 3.3×10-6 |
红霉素 | - | 8.6×10-5 |
组 | 处理 | 给药路径 | |
1 | 对照 | - | - |
2 | 派克昔林 | 40mg/kg(1/2MTD) | 口服 |
3 | 红霉素 | 10mg/kg | 腹腔注射 |
4 | PTK787/ZK222584 | 50mg/kg | 口服 |
Claims (21)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52134604P | 2004-04-06 | 2004-04-06 | |
US60/521,346 | 2004-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1938025A true CN1938025A (zh) | 2007-03-28 |
Family
ID=35124826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800105055A Pending CN1938025A (zh) | 2004-04-06 | 2005-04-06 | 影响血管生成的化合物及其使用方法 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1737452A1 (zh) |
JP (1) | JP2007532536A (zh) |
CN (1) | CN1938025A (zh) |
AU (1) | AU2005230811A1 (zh) |
CA (1) | CA2560416A1 (zh) |
NZ (1) | NZ550088A (zh) |
WO (1) | WO2005097121A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
EP2468318A1 (en) * | 2005-07-12 | 2012-06-27 | DMI Biosciences, Inc. | Methods and products for treatment of diseases |
AU2006283174A1 (en) * | 2005-08-24 | 2007-03-01 | Cell-Matrix, Inc. | Combination therapies for inhibiting integrin-extracellular matrix interactions |
CA2622312A1 (en) * | 2006-01-30 | 2007-08-02 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
GB0908193D0 (en) | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
MX2011012310A (es) | 2009-05-20 | 2012-04-11 | Heart Metabolics Ltd | Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen). |
DK2554171T3 (da) | 2009-06-22 | 2014-11-17 | Ampio Pharmaceuticals Inc | Fremgangsmåde til behandling af sygdomme |
CN104968350A (zh) | 2012-12-19 | 2015-10-07 | 安皮奥制药股份有限公司 | 疾病的治疗方法 |
WO2015131231A1 (en) * | 2014-03-03 | 2015-09-11 | Adelaide Research & Innovation Pty Ltd | Methods for using (-)-perhexiline |
US20170114323A1 (en) * | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
US10124008B2 (en) | 2014-06-23 | 2018-11-13 | Wisconsin Alumni Research Foundation | Use of inhibitors of acid sphingomyelinase to treat acquired and inherited retinal degenerations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5512591A (en) | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
US6413967B1 (en) * | 1995-03-30 | 2002-07-02 | The University Of Virginia Patents Foundation | Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy |
AUPN380695A0 (en) * | 1995-06-23 | 1995-07-20 | Queen Elizabeth Hospital, The | Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions |
AU727080B2 (en) * | 1997-06-30 | 2000-11-30 | Allergan, Inc. | Calcium blockers to treat proliferative vitreoretinopathy |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
US20020137755A1 (en) * | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
US20030162824A1 (en) * | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
CA2499484A1 (en) | 2002-09-19 | 2004-04-01 | Medigene Aktiengesellschaft | Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases |
-
2005
- 2005-04-06 CN CNA2005800105055A patent/CN1938025A/zh active Pending
- 2005-04-06 WO PCT/SE2005/000506 patent/WO2005097121A1/en active Application Filing
- 2005-04-06 JP JP2007507279A patent/JP2007532536A/ja active Pending
- 2005-04-06 EP EP05730890A patent/EP1737452A1/en not_active Ceased
- 2005-04-06 CA CA002560416A patent/CA2560416A1/en not_active Abandoned
- 2005-04-06 AU AU2005230811A patent/AU2005230811A1/en not_active Abandoned
- 2005-04-06 NZ NZ550088A patent/NZ550088A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2007532536A (ja) | 2007-11-15 |
WO2005097121A1 (en) | 2005-10-20 |
CA2560416A1 (en) | 2005-10-20 |
EP1737452A1 (en) | 2007-01-03 |
NZ550088A (en) | 2009-08-28 |
AU2005230811A1 (en) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1938025A (zh) | 影响血管生成的化合物及其使用方法 | |
Alexandre et al. | Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms | |
Guariento et al. | Preischemic autologous mitochondrial transplantation by intracoronary injection for myocardial protection | |
Danchin et al. | Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis | |
Brack et al. | The mechanical uncoupler blebbistatin is associated with significant electrophysiological effects in the isolated rabbit heart | |
CN102105151B (zh) | Cdk抑制剂在治疗神经胶质瘤中的应用 | |
Shukla et al. | Heart failure hospitalization is more common in pacemaker patients with sinus node dysfunction and a prolonged paced QRS duration | |
ES2521679T3 (es) | Terapia específica usando ligandos de integrinas para el tratamiento del cáncer | |
CN105246889B (zh) | 氟化整联蛋白拮抗剂 | |
US20040048906A1 (en) | Therapeuctic combination | |
Plewka et al. | Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction | |
CN107921062A (zh) | 组织修复和再生方法 | |
Shore et al. | eRADicAte: a prospective evaluation combining radium-223 dichloride and abiraterone acetate plus prednisone in patients with castration-resistant prostate cancer | |
de la Fuente et al. | Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study) | |
Knackstedt et al. | Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation | |
Jackson et al. | Effect of atenolol on heart rate, arrhythmias, blood pressure, and dynamic left ventricular outflow tract obstruction in cats with subclinical hypertrophic cardiomyopathy | |
Hochstadt et al. | Effect of pacemaker implantation after transcatheter aortic valve replacement on long-and mid-term mortality | |
Ebersole et al. | Comparison of exercise and adenosine technetium-99m sestamibi myocardial scintigraphy for diagnosis of coronary artery disease in patients with left bundle branch block | |
Curila et al. | Bipolar anodal septal pacing with direct LBB capture preserves physiological ventricular activation better than unipolar left bundle branch pacing | |
CN110368388A (zh) | 1-脱氧野尻霉素在治疗糖尿病心肌病和肝损伤中的应用 | |
Reddy et al. | The Effect of β‐Blockers on Health‐Related Quality of Life in Patients with Heart Failure | |
CN104688784B (zh) | 银杏内酯在制备降血压的药物中的用途 | |
Bao et al. | Artemisinin and its derivate alleviate pulmonary hypertension and vasoconstriction in rodent models | |
CN102048727A (zh) | 芒柄花黄素在制备抑制血管生成药物中的应用 | |
CN102600146B (zh) | 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Correction of invention patent gazette |
Correction item: Applicant address Correct: Stockholm False: Gothenburg Number: 13 Page: 734 Volume: 23 |
|
CI02 | Correction of invention patent application |
Correction item: Applicant address Correct: Stockholm False: Gothenburg Number: 13 Page: The title page Volume: 23 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT ADDRESS; FROM: GOTHENBURG, SWEDEN TO: STOCKHOLM, SWEDEN |
|
ERR | Gazette correction |
Free format text: CORRECT: APPLICANT ADDRESS; FROM: GOTHENBURG, SWEDEN TO: STOCKHOLM, SWEDEN |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1099233 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070328 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1099233 Country of ref document: HK |